Clinical trial Recruiting at 1 site Interventional Ages 18 to 75

Effect of blood volume management during bone tumor surgery

Official title: The Effect of Acute Normovolemic Hemodilution on Intraoperative Allogeneic Transfusion in Bone Tumor Surgery: a Prospective, Randomized Controlled Trial

Run by Second Affiliated Hospital, Zhejiang University, School of Medicine · NCT06459141 · Data updated 2026-11-12

This study is testing if a method called acute normovolemic hemodilution can help reduce the need for blood transfusions during bone tumor surgeries for patients aged 18 to 75.

Quick facts

Study typeInterventional
Ages18 Years to 75 Years
SexAll
Enrollment150 (estimated)
SponsorSecond Affiliated Hospital, Zhejiang University, School of Medicine
Academic / other
Locations1 site (Hangzhou, Zhejiang)
StatusRecruiting
StartedJune 7, 2024
Main results expectedMay 2028
Study endsMay 2028
Registry record updatedJune 25, 2026
Trial IDNCT06459141 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 to 75 who are scheduled for elective bone tumor resection surgery with a preoperative hemoglobin level of at least 11 g/dL.

Probably not a fit

Patients with conditions such as cardiopulmonary insufficiency, hepatic and renal dysfunction, or those undergoing palliative operations may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial investigates the impact of acute normovolemic hemodilution (ANH) on reducing the need for blood transfusions during bone tumor surgeries. It aims to determine if ANH, when combined with goal-directed fluid therapy, can minimize intraoperative allogeneic red blood cell transfusions, which are associated with increased postoperative complications. The study will involve patients aged 18 to 75 undergoing elective bone tumor resection, assessing blood loss and transfusion requirements. By evaluating the efficacy of ANH in this context, the trial seeks to improve patient outcomes and reduce the risks associated with blood transfusions.

Why it matters

Potential benefit: If successful, this approach could significantly reduce the need for blood transfusions and improve recovery outcomes for patients undergoing bone tumor surgery.

How similar studies have gone: While the efficacy of acute normovolemic hemodilution has been controversial, this study aims to clarify its role in a specific surgical context, making it a novel approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. age 18 to 75 years;
2. undergoing elective bone tumor resection surgery;
3. preoperative hemoglobin ≥11 g/dL;

Exclusion Criteria:

1. using a tourniquet;
2. palliative operation or minimally invasive surgery;
3. BMI\<18.5 or \>30Kg/m\^2;
4. international normalized ratio (INR) \>1.5 or platelet count \<100 × 10\^9/L;
5. cardiopulmonary insufficiency;
6. hepatic and renal dysfunction;
7. active infectious disease;
8. allergy to succinyl gelatin;
9. pregnancy;
10. declined participation in the study or declined blood transfusion

Where it's running

  • The Second Affiliated Hospital of Zhejiang University anesthesiology department
    Hangzhou, Zhejiang, China
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.